ID30237A - KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES - Google Patents

KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES

Info

Publication number
ID30237A
ID30237A IDW00200101612A ID20011612A ID30237A ID 30237 A ID30237 A ID 30237A ID W00200101612 A IDW00200101612 A ID W00200101612A ID 20011612 A ID20011612 A ID 20011612A ID 30237 A ID30237 A ID 30237A
Authority
ID
Indonesia
Prior art keywords
insulin
fbpase
obstacles
plants
combination
Prior art date
Application number
IDW00200101612A
Other languages
English (en)
Indonesian (id)
Inventor
Mark D Erion
Paul Van Poelje
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of ID30237A publication Critical patent/ID30237A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IDW00200101612A 1998-12-24 1999-12-22 KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES ID30237A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
ID30237A true ID30237A (id) 2001-11-15

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101612A ID30237A (id) 1998-12-24 1999-12-22 KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES

Country Status (25)

Country Link
EP (1) EP1143955B1 (zh)
JP (1) JP2003515523A (zh)
KR (3) KR20070046210A (zh)
CN (3) CN100352505C (zh)
AT (1) ATE300288T1 (zh)
AU (1) AU771039B2 (zh)
BR (1) BR9917005A (zh)
CA (1) CA2354053A1 (zh)
CZ (1) CZ20012353A3 (zh)
DE (1) DE69926400T2 (zh)
DK (1) DK1143955T3 (zh)
ES (1) ES2246586T3 (zh)
HK (1) HK1046863B (zh)
HU (1) HUP0402506A3 (zh)
ID (1) ID30237A (zh)
IL (2) IL143569A0 (zh)
MX (1) MXPA01006511A (zh)
NO (1) NO20013115L (zh)
NZ (1) NZ512219A (zh)
PL (1) PL352756A1 (zh)
PT (1) PT1143955E (zh)
RU (2) RU2227749C2 (zh)
SK (1) SK9172001A3 (zh)
WO (1) WO2000038666A2 (zh)
ZA (1) ZA200105016B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
SK286080B6 (sk) 1998-09-09 2008-03-05 Metabasis Therapeutics, Inc. Heterocyklické aromatické zlúčeniny obsahujúce fosfonátovú skupinu, ich použitie a farmaceutická kompozícia obsahujúca uvedené zlúčeniny
AU784370B2 (en) 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
WO2001066553A2 (en) 2000-03-08 2001-09-13 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
EP1372660A2 (en) * 2000-07-06 2004-01-02 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
WO2002040458A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Derives d'isoxazole
CA2485597C (en) 2002-05-13 2013-07-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
JP4476811B2 (ja) 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Pmeaおよびそのアナログの新規ホスホン酸系プロドラッグ
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1611112B1 (en) * 2003-02-11 2012-08-22 Vernalis (Cambridge) Limited Isoxazole compounds as inhibitors of heat shock proteins
EP3002283B1 (en) 2003-12-26 2017-06-14 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
BRPI0519006A2 (pt) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
EP1825854A1 (en) * 2004-12-15 2007-08-29 Daiichi Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
JPWO2006137527A1 (ja) 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びage生成阻害剤
EP0427799B1 (en) * 1989-01-24 1994-11-30 Gensia, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ATE253073T1 (de) * 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase

Also Published As

Publication number Publication date
KR20010099942A (ko) 2001-11-09
IL143569A0 (en) 2002-04-21
PT1143955E (pt) 2005-11-30
NZ512219A (en) 2004-12-24
DK1143955T3 (da) 2005-11-14
CZ20012353A3 (cs) 2001-12-12
CN1350466A (zh) 2002-05-22
AU771039B2 (en) 2004-03-11
NO20013115D0 (no) 2001-06-21
EP1143955A2 (en) 2001-10-17
MXPA01006511A (es) 2004-03-19
KR100689943B1 (ko) 2007-03-08
CN100352505C (zh) 2007-12-05
ATE300288T1 (de) 2005-08-15
RU2003132054A (ru) 2005-04-20
HK1046863A1 (en) 2003-01-30
RU2227749C2 (ru) 2004-04-27
IL143569A (en) 2006-06-11
WO2000038666A3 (en) 2001-11-29
EP1143955A3 (en) 2002-08-28
KR20060114724A (ko) 2006-11-07
AU2058300A (en) 2000-07-31
CA2354053A1 (en) 2000-07-06
PL352756A1 (en) 2003-09-08
JP2003515523A (ja) 2003-05-07
EP1143955B1 (en) 2005-07-27
BR9917005A (pt) 2002-04-02
SK9172001A3 (en) 2002-04-04
WO2000038666A2 (en) 2000-07-06
ZA200105016B (en) 2002-09-19
DE69926400T2 (de) 2006-05-24
CN1714866A (zh) 2006-01-04
CN101164618A (zh) 2008-04-23
KR20070046210A (ko) 2007-05-02
DE69926400D1 (de) 2005-09-01
NO20013115L (no) 2001-08-24
HUP0402506A2 (hu) 2005-04-28
ES2246586T3 (es) 2006-02-16
HUP0402506A3 (en) 2007-05-29
HK1046863B (zh) 2008-07-25

Similar Documents

Publication Publication Date Title
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
TW200502385A (en) Modulation of forkhead box o1a expression
DE60118723D1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
MXPA02001099A (es) Compuestos para modular el receptor rage.
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
SI1865990T1 (sl) Postopek za zdravljenje diabetesa tipa 2
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ATE526992T1 (de) Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung
AP9801416A0 (en) Method Of treating a plant disease.
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
SE9702993D0 (sv) Anti-mikrobial komposition
ATE422668T1 (de) Verfahren zur identifizierung von modulatoren der glucoseaufnahme
UA32167A (uk) Спосіб прогнозування появи негативної реакції крові при плануванні магнітотерапії, лазеротерапії, увч-терапії у хворих з травматичним переломом та остеомієлітом нижньої щелепи
NO994394L (no) Aktivert vitamin K-avhengig blodfaktor og fremgangsmÕte for fremstilling av denne